• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RRP
Click for more information
0.00% 8.5¢

REALM RESOURCES LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
RRPPreliminary Final ReportPRICE SENSITIVE28/02/11
RRPAppendix 4C - quarterlyPRICE SENSITIVE28/01/11
RRPResponse to ASX Price and Volume QueryPRICE SENSITIVE18/11/10
RRPMarket UpdatePRICE SENSITIVE17/11/10
RRPAppendix 4C - quarterlyPRICE SENSITIVE29/10/10
RRPCompany Update - South African ProjectsPRICE SENSITIVE01/09/10
RRPHalf Yearly Report and AccountsPRICE SENSITIVE31/08/10
RRPAppendix 4C - quarterlyPRICE SENSITIVE27/07/10
RRPPreliminary Final Report
28/02/11PRICE SENSITIVE
RRPAppendix 4C - quarterly
28/01/11PRICE SENSITIVE
RRPResponse to ASX Price and Volume Query
18/11/10PRICE SENSITIVE
RRPMarket Update
17/11/10PRICE SENSITIVE
RRPAppendix 4C - quarterly
29/10/10PRICE SENSITIVE
RRPCompany Update - South African Projects
01/09/10PRICE SENSITIVE
RRPHalf Yearly Report and Accounts
31/08/10PRICE SENSITIVE
RRPAppendix 4C - quarterly
27/07/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals Nanocap Tyranna Resources (ASX:TYX) has reported winding up lithium drilling at its Angolan Namibe Lithium Project (NLP).
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Recce scores $6.75M R&D rebate Recce Pharmaceuticals (ASX: RCE) has received a cash refund of $6,751,176 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.